Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
ATAC trial data reported comparing anastrozole to tamoxifen
December 28th, 2004
New data presented on December 8, 2004, from the world's largest early breast cancer treatment trial (ATAC) indicate that Arimidex (anastrazole; AstraZeneca) reduced the relative risk of breast cancer recurrence by 17% over tamoxifen in the clinically relevant hormone receptor-positive patients for whom Arimidex is indicated. The presentation also reviewed the safety profile of Arimidex compared to tamoxifen after 68 months of follow-up. Arimidex and tamoxifen remain the only drugs approved by the U.S. Food and Drug Administration for the primary (treatment following surgery, with or without radiation) adjuvant treatment of hormone receptor-positive...
Source: Cancer Weekly (2004-12-28)
|
